Allogene Therapeutics, Inc. (ALLO )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ALLO
- Company Allogene Therapeutics, Inc.
- Price $1.88
- Changes Percentage -8.98
- Change -0.185
- Day Low $1.84
- Day High $2.09
- Year High $4.89
- Year Low $1.32
- Market Cap $392,086,640
- Price Avg 50 EMA (D) $1.96
- Price Avg 200 EMA (D) $2.4
- Exchange NASDAQ
- Volume 1,226,339
- Average Volume 5,439,505
- Open $2.04
- Previous Close $2.06
- EPS -1.55
- PE -1.21
- Earnings Announcement 2025-03-13 20:00:00
- Shares Outstanding $209,672,000
Company brief: ALLOGENE THERAPEUTICS, INC. (ALLO )
- Healthcare
- Biotechnology
- Dr. David D. Chang M.D., Ph.D.
- https://www.allogene.com
- US
- N/A
- 10-11-2018
- US0197701065
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.